CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
6.2900
+0.1700 (2.78%)
NASDAQ · Last Trade: Aug 27th, 6:11 PM EDT
Detailed Quote
| Previous Close | 6.120 |
|---|---|
| Open | 6.250 |
| Bid | 5.880 |
| Ask | 6.550 |
| Day's Range | 5.850 - 6.385 |
| 52 Week Range | 4.930 - 221.94 |
| Volume | 9,947 |
| Market Cap | 3.61M |
| PE Ratio (TTM) | 0.0005 |
| EPS (TTM) | 13,247.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 77,619 |
Chart
About CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CNS Pharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) cancers. The company specializes in formulating and advancing drug candidates that target various forms of brain tumors, aiming to improve treatment options and outcomes for patients faced with challenging diagnoses. Through its research and development efforts, CNS Pharmaceuticals strives to address significant unmet medical needs in the oncology sector, leveraging scientific expertise and novel approaches to bring potential new therapies to market. Read More
News & Press Releases
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in novel treatments for primary and metastatic brain cancers, was featured in the latest episode of The BioMedWire Podcast hosted by IBN. CEO John Climaco detailed the company’s mission to address the urgent unmet need in glioblastoma, its seamless transition from the berubicin trial to advancing the TPI 287 program, and the broader market opportunities in aggressive cancers such as triple-negative breast cancer with brain metastases. Climaco underscored CNS Pharmaceuticals’ operational expertise, commitment to accelerating development, and vision to bring hope to patients facing limited treatment options.
Via Investor Brand Network · August 27, 2025
Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth
According to new research conducted by a team at University College London, blocking the brain damage caused by glioblastoma could keep the patient’s brain working better for a much longer time and also slow the pace at which the tumor grows .
Via Investor Brand Network · August 26, 2025
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, driven by reduced Berubicin trial costs. R&D expenses rose to $1.2 million from $1.1 million on preparation for a TPI 287 trial, while G&A fell to $1.2 million from $1.4 million on lower legal, travel and stock-based compensation costs. The Company ended the quarter with $12.1 million in cash, sufficient to fund operations into the second half of 2026. CEO John Climaco said CNS is on track to begin a Phase 2 study of TPI 287 for glioblastoma multiforme (GBM) in the first half of 2026, following its Orphan Drug Designation for multiple CNS indications and promising Phase 1 results showing blood brain barrier penetration and tumor response.
Via Investor Brand Network · August 15, 2025
Strong cash position of $12.1 million expected to fund operations into the second half of 2026
Via ACCESS Newswire · August 15, 2025
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025.
Via Investor Brand Network · August 14, 2025
What Women Need to Know About Benign Brain Tumors
It is easy to shrug off forgetfulness or a headache as stress. However, this isn’t always the case as those symptoms could point to the possibility of a tumor in the brain. For women, this risk is even higher given that women make up 62.9% of people who develop noncancerous brain tumors. It is therefore important to know what to look out for, and which steps to take.
Via Investor Brand Network · August 14, 2025
- Live video webcast on Tuesday, August 19th at 2:40 PM ET
Via ACCESS Newswire · August 14, 2025
Study Reveals Potential Way to Treat Pediatric Gliomas
A joint study between the Broad Institute and the Dana-Farber Cancer Institute has discovered a new and potentially effective way to treat pediatric gliomas. The research revealed that a percentage of children diagnosed with gliomas, an incredibly common type of pediatric brain cancer, may respond to certain inhibitors that have already been approved by the U.S. Food and Drug Administration.
Via Investor Brand Network · August 11, 2025
Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment
Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams could rely on to predict which patients having glioblastoma stand higher chances of benefiting from bevacizumab, a cancer drug.
Via Investor Brand Network · August 1, 2025
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers of the brain and central nervous system, announced that CEO John Climaco participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. Climaco shared his personal journey, leadership vision and enthusiasm for the company’s development programs. The webcast is available on virtualinvestorco.com and the Events section of the CNS Pharmaceuticals website.
Via Investor Brand Network · July 22, 2025
Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer
A team of researchers testing an experimental messenger RNA (mRNA) vaccine managed to ramp up the ability of immunotherapy to combat tumors in a study using mouse models. This finding potentially brings scientists one step closer to developing universal vaccines that can supercharge the immune system in its fight against cancer.
Via Investor Brand Network · July 22, 2025
– Video webcast now available on-demand
Via ACCESS Newswire · July 22, 2025
- Video webcasts from participating companies now available here
Via ACCESS Newswire · July 22, 2025
New Machine Learning Model Predicts Cancer Severity, Aids Treatment Planning
A joint team of Polish and Brazilian researchers has developed a new machine learning model that can help improve cancer treatment planning by accurately predicting cancer severity. The model uses machine learning technology to identify specific proteins in tumor cells and predict how aggressive the tumors will be, allowing physicians to tailor cancer treatments for their patients.
Via Investor Brand Network · July 21, 2025
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments to warrants and equity awards. No fractional shares will be issued—holders will receive cash instead. The authorized share count will be reduced to 25 million, while par value remains $0.001. The move is designed to affect all shareholders uniformly.
Via Investor Brand Network · July 18, 2025
HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP" but will trade under the following new CUSIP number: 18978H508.
Via ACCESS Newswire · July 18, 2025
New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer
A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%.
Via Investor Brand Network · July 10, 2025
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco’s participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company’s lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts.
Via Investor Brand Network · July 9, 2025
HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals recently participated in a Virtual Investor CEO Connect segment.
Via ACCESS Newswire · July 9, 2025
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · July 3, 2025
Via Benzinga · July 3, 2025
Research Links Key Proteins to the Growth of Brain Tumors
University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive.
Via Investor Brand Network · June 27, 2025
New Scanning Method Could Improve How Brain Tumors are Treated
Researchers from NHS Grampian and the University of Aberdeen have been granted funding to study a novel scanning method that could improve how physicians scan and treat brain tumors. The Scottish Government awarded the research team nearly $470,000 in funding to investigate new means of treating glioblastomas, an aggressive brain tumor that affects tens of thousands of Americans each year. Glioblastomas are responsible for 48% of brain tumors in the primary malignant class and are estimated to take 10,000 American lives each year.
Via Investor Brand Network · June 25, 2025
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar
CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications.
Via Investor Brand Network · June 24, 2025
Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar
Via ACCESS Newswire · June 24, 2025